Form 4: Rhythm Pharmaceuticals Insider Trades Common Stock

Alastair Garfield, Chief Scientific Officer at Rhythm Pharmaceuticals, reported transactions involving common stock and restricted stock units.

Summary

• Alastair Garfield, Chief Scientific Officer of Rhythm Pharmaceuticals, Inc., engaged in transactions on July 1, 2026.
• Garfield acquired 4,445 shares of common stock via restricted stock units (RSUs).
• Additionally, 2,150 shares were disposed of to cover tax withholding obligations upon the vesting of RSUs.
• Following these transactions, Garfield beneficially owns 10,058 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, reflecting routine executive compensation and tax management rather than significant strategic shifts or performance indicators.

Positives

• Acquisition of 4,445 shares of common stock through RSUs indicates continued equity participation.
• The vesting of RSUs suggests progress and achievement of performance or service milestones.

Negatives

• 2,150 shares were disposed of to cover tax withholding, reducing the net increase in directly held shares.

Future Outlook

The RSUs vest in tranches of 25% on each of the first four anniversaries of July 1, 2024, subject to continued service. This indicates a structured equity incentive plan tied to ongoing employment.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard for reporting insider transactions, providing transparency into executive stock ownership and activity within the biopharmaceutical sector.

Stakeholder Impact

• Shareholders: Increased transparency into executive stock ownership and potential dilution from RSU vesting.
• Employees: Reinforces the company's use of equity-based compensation to retain key scientific talent.
• Management: Alastair Garfield's continued equity stake aligns his interests with long-term company performance.

Next Steps

• Continued vesting of restricted stock units over the next two years, contingent on Alastair Garfield's continued service.
• Potential future transactions by Alastair Garfield as RSUs vest or based on personal financial planning.

Key Dates

Keywords

Rhythm Pharmaceuticals, RYTM, Form 4, Insider Trading, Stock Transaction, Restricted Stock Units, Beneficial Ownership, Securities Exchange Act